Form 4: Alkermes Director Exercises Vested Stock Units, Sells Shares for Tax Obligations

Alkermes plc Director Brian P. McKeon exercised restricted stock units and sold a portion of the resulting ordinary shares to cover tax withholding obligations.

Summary

• Brian P. McKeon, a Director of Alkermes plc, exercised 8,013 restricted stock units (RSUs) on May 31, 2025.
• Each RSU represents a contingent right to receive one ordinary share, and the award was fully vested.
• Concurrently, Mr. McKeon disposed of 1,924 ordinary shares at a price of $30.61 per share to satisfy tax withholding obligations related to the RSU exercise.
• Following these transactions, Mr. McKeon directly beneficially owns 33,869 ordinary shares and indirectly owns 10,000 ordinary shares through The Brian P. McKeon Trust.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction involving the exercise of vested equity and a sale to cover tax obligations, which is a common and expected event for directors receiving equity compensation. It does not indicate a significant positive or negative shift in company prospects.

Positives

• The exercise of restricted stock units indicates the vesting of previously granted equity compensation, aligning management's interests with shareholders.

Negatives

• A portion of the shares acquired from the RSU exercise was sold to cover tax obligations, which is a common practice but reduces the director's direct ownership slightly.

Risks

• No specific risks are identified in this Form 4 filing beyond the general market risks associated with holding company stock.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The filing indicates that the restricted stock unit award is fully vested in accordance with its terms.

Industry Context

This is a routine insider transaction (exercise of equity compensation and subsequent tax-related sale) and does not provide specific insights into broader industry trends or competitive landscape for Alkermes plc, which operates in the biopharmaceutical sector.

Comparison to Industry Standards

• This document reports a standard insider transaction involving the exercise of restricted stock units and a sale to cover tax obligations. Such transactions are common across all industries, including the biopharmaceutical sector, for executives and directors receiving equity compensation. There are no specific comparable companies or projects mentioned to assess against industry benchmarks.

Related Party Transactions

• Brian P. McKeon indirectly owns 10,000 ordinary shares through The Brian P. McKeon Revocable Trust, dated April 12, 2007, and amended and restated on February 8, 2019, of which he and his wife are trustees and immediate family members are beneficiaries.

Stakeholder Impact

• Shareholders: The transaction represents a routine exercise of equity compensation and a tax-related sale by a director, which is unlikely to have a material impact on the company's stock price or long-term shareholder value.

Next Steps

• The document does not specify any future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Keywords

Alkermes plc, ALKS, Form 4, Insider Transaction, Restricted Stock Units, RSU Exercise, Director Stock Sale, Equity Compensation, Tax Withholding